MedPath

Removable GORE VIABIL® Biliary Endoprosthesis for Treatment of Benign Biliary Strictures

Not Applicable
Completed
Conditions
Biliary Strictures
Interventions
Device: GORE® VIABIL® Biliary Endoprosthesis
Registration Number
NCT01343160
Lead Sponsor
W.L.Gore & Associates
Brief Summary

The purpose of this study is to generate clinical data to support the use of GORE® VIABIL® Biliary Endoprosthesis in the endoscopic and percutaneous treatment of benign biliary strictures.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
43
Inclusion Criteria
  • Subject is diagnosed with treatable benign biliary stricture which necessitates the need for implantation of a biliary endoprosthesis
  • Subject is ≥18 years of age
  • Subject is able to comply with study protocol and follow-up requirements
  • Written informed consent is obtained using the Investigational Review Board (IRB)/Ethics Committee (EC) approved consent form
Exclusion Criteria
  • Subject anatomy ruling out covered self expanding metal stent use (e.g. above hilar region)
  • Treatment of stricture would require placement of a covered biliary endoprosthesis within a previously placed bare metal stent
  • The subject has malignant biliary disease
  • Subject has known pregnancy
  • Participated in protocol involving investigational drug or device within 90 days prior to entry into this study

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
GORE VIABIL® Biliary EndoprosthesisGORE® VIABIL® Biliary EndoprosthesisPlacement of GORE VIABIL® Biliary Endoprosthesis to establish duct patency
Primary Outcome Measures
NameTimeMethod
Safe Stent RemovalUpon Removal

The stent removal is considered safe when the Study Device is removed successfully and without SAEs.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Klinikum Ludwigsburg

🇩🇪

Ludwigsburg, Germany

© Copyright 2025. All Rights Reserved by MedPath